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Objectives: Oxidative stress biomarkers as reactive oxygen species are induced by
the sustained activation of neutrophils and other CF-derived defects in the lung of
CF patients. Observed defects include an impaired glutathione (GSH) metabolism.
Its supplementation may counterbalance the oxidative stress. A randomized, single
blind controlled trial of inhaled GSH versus placebo (NCT01450267) is underway in
order to evaluate the effect of GSH in cohort of CF patients. We report preliminary
data on tolerability to GSH in a pediatric subset of enrolled patients.
Methods: 48 CF patients (F 23, age M±DS 13.53 yrs), in regular follow up at
the Regional Pediatric CF Center of Naples, were enrolled for RCT. The main
inclusion criteria were: CF diagnosis by sweat test and/or two CF causing mutations,
age of patients >6 yrs, FEV1% >40% of the predicted value, negative culture for
Burkholderia cepacia. Spirometry was performed before and 10 and 60 minutes
after GSH inhalation test (10mg/kg, maximum dosage 600mg/dose) in order to
assess tolerability.
Conclusions: No patients showed a decrease in FEV1% >15% after GSH inhalation
as deﬁned in the study design. A statistically signiﬁcant increase was observed
for FEF25−75% after 10 and 60 minutes from inhalation (FEF25−75 M±DS:
T0 71.64±33.35 VS T10 76.37±36.73; p< 0.02 and T0 71.64±33.35 VS T60:
80.26±35.25; p< 0.0001) and for FEV1% after 60 minutes from inhalation (FEV1
M±DS: T0 97.90±21.03 VS T60 100.01±19.42; p< 0.01). No side effects were
reported. On the basis of these preliminary results we are currently evaluating the
efﬁcacy of inhaled GSH on pulmonary function and inﬂammatory markers within
a 12 months therapy.
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Objectives: Chronic lung inﬂammation and bacterial infections cause much of
the morbidity and mortality in patients with CF. Previous studies have shown
that hyaluronan (HA) may exert a protective effect against injury in experimental
models of chronic respiratory diseases. Our objective was to examine if exogenous
administration of nebulized HA might interfere with lung inﬂammation in vivo in
mouse models of CF.
Methods: F508del homozygous mice (CftrF508del) and transgenic mice overex-
pressing the ENaC channel b-subunit (Scnn1b-Tg) were treated with nebulized
HA (0.5mg per animal in saline solution for 30 minutes once daily for 7 days).
TNFa expression, MIP2 levels, MPO activity and macrophage inﬁltration were
assessed on lung tissues. CF cell lines were cultured with HA (24 h, 100mg/ml) and
Reactive Oxygen Species (ROS), Tissue Transglutaminase (TG2) SUMOylation,
PPARg and phospho-p42/p44 levels were measured by dichlorodihydroﬂuorescein
assay, or FRET microscopy or immunoblots.
Conclusions: Nebulized HA reduced TNFa mRNA levels (52±30%, and
64±32%, p< 0.005), MIP2 (56±9% and 79±7%, p< 0.05), MPO protein lev-
els (from 1780.47±973.18 to 548.84±386.64 and from 2325.25±840.83 to
1003.12±722.13 nmol/min/ml, p< 0.05), CD68+ cells counts in lung tissues (from
102.4±27.1 to 36.6±19.2 and from 62.4±28.2 to 25.8±13.2 per mm2 of tissue,
p< 0.005) in both CftrF508del and Scnn1b-Tg mice, respectively, as compared to
saline-treated mice. HA reduced ROS, TG2 SUMOylation, TG2 enzyme activity,
phospho-p42−44 and increased PPARg protein in both IB3−1 and CFBE41o− cell
lines (p< 0.05). Inhaled HA could be effective as a potential anti-inﬂammatory
drug in CF therapy.
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Pseudomonas aeruginosa (PA) is a common cause of morbidity in cystic ﬁbrosis
patients. Studies have demonstrated that OligoG, a deﬁned alginate oligomer nano-
medicine, potentiates the activity of conventional antibiotics by up to 500-fold
against a range of multi-drug resistant Gram-negative bacteria. Using nanoscale
analysis (surface charge and sizing measurements, and atomic force microscopy)
interaction of OligoG with the surface of the PA strain PAO1 was characterised.
Sizing analysis (employing the dynamic light scattering process) showed OligoG
treatment resulted in a 2 fold increase in bacterial size (1500±220 nm), which
was associated with cell-clumping. Hydrodynamic shear experiments demonstrated
that this interaction was not displaced by centrifugation (5,500 g). Surface-charge
distribution, characterised using zeta potential measurements, demonstrated the
bimodal, heterogeneity of surface charge in PA (peak 1: −28.6±1.1mV, peak2:
−50.2±2.2mV). OligoG treatment resulted in modulation of the bacterial surface
charge with the development of a secondary, more negative zeta-potential peak
(−57.8±2.7mV). These results demonstrate that OligoG binds to the bacteria
cell surface, causing it to become more negatively charged. The changes brought
about by OligoG binding may inﬂuence microbial cell adhesion and hence bioﬁlm
formation. Further studies are ongoing to further elucidate these post-binding events.
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The importance of bioﬁlms in chronic human disease is increasingly recognised in
modulating the local immune response and reducing the efﬁciacy of conventional
antimicrobial therapies. We have previously shown, using scanning electron and
confocal laser scanning microscopy, that the clinically safe alginate oligomer
OligoG disrupts Pseudomonas aeruginosa PAO1 bioﬁlm formation. The ability of
OligoG to affect established bioﬁlms was quantiﬁed using atomic force microscopy
(AFM) to map differences in the mechanical properties of bioﬁlm surfaces. Dried
bioﬁlms were imaged in air using tapping mode operation with silicon nitride non-
contact cantilevers. AFM imaging and force measurements demonstrated obvious
differences in the surface mechanical characteristics of the OligoG-treated and
untreated bioﬁlms. OligoG-treated bioﬁlms exhibited signiﬁcantly lower Young’s
moduli, and hence were less mechanically robust than the untreated bioﬁlm
(p< 0.05). When treated and untreated bioﬁlms were subject to a controlled
hydrodynamic shear, the remaining bioﬁlms had signiﬁcant differences in surface
roughness as measured from AFM images (35.2±7.6 nm vs 12.1±5.4 nm). These
studies demonstrate the utility of AFM as a quantitative approach to investigate, at
the nanoscale, the interaction of potential therapies on bioﬁlm structures. They also
show the potential ability for OligoG treatment to modulate bioﬁlm structure and
maintenance in vivo.
